

Supporting Information

Synthesis of Pyrazolone Fused Benzodiazepines via Rh(III)-Catalyzed [4+3] Annulation of 1-Phenylpyrazolidinones with Propargyl Alcohols

Linghua Zhang, Yuanshuang Xu, Xiaopeng Zhang, Xinying Zhang*, and Xuesen Fan*

Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, China

E-mail: xinyingzhang@htu.cn; xuesen.fan@htu.cn

Table of Contents

I	General experimental information	S2
II	Experimental procedures and spectroscopic data	S3-S29
III	Mechanism studies	S30-S31
IV	Copies of NMR spectra of 3a-3ee	S32-S70
V	Copies of NMR spectra of 5a-5m	S71-S85
VI	Copies of NMR spectra of 7a-7q	S86-S105
VII	Copies of NMR spectra of 8 and 9	S106-S107
VIII	X-ray crystal structure and data of 3a	S108-S109
IX	X-ray crystal structure and data of 5a	S110-S111
X	References	S112


I. General experimental information

Commercial reagents were used without further purification. 1-Phenylpyrazolidinones (**1**),^[1,2] propargyl alcohols (**2**, **4**, **6**),^[3,4] and $[\text{RhCp}^*\text{Cl}_2]_2$ ^[5] were prepared based on literature procedures. Melting points were recorded with a micro melting point apparatus and uncorrected. The ^1H NMR spectra were recorded at 400 MHz or 600 MHz. The ^{13}C NMR spectra were recorded at 100 MHz or 150 MHz. The ^{19}F NMR spectra were recorded at 376 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), dd (doublet of doublets), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. High resolution mass spectra (HRMS) were obtained *via* ESI mode by using a MicrOTOF mass spectrometer. All reactions were monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data


1. Typical procedure for the synthesis of 3a and spectroscopic data of 3a-3ee, 5a-5m and 7a-7q

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 48.7 mg, 0.3 mmol), toluene (2 mL), [RhCp*Cl₂]₂ (4.7 mg, 0.0075 mmol), Zn(OAc)₂ (27.5 mg, 0.15 mmol), NaOAc (12.3 mg, 0.15 mmol) and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 48.1 mg, 0.3 mmol). The resulting mixture was stirred at 100 °C (oil bath) for 4 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **3a** (80.5 mg, 88%). **3b-3ee**, **5a-5m** and **7a-7q** were obtained in a similar manner.



5,5-Dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (**3a**)


White solid (80.5 mg, 88%), mp 173.2-174.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.67 (s, 6H), 2.77 (t, *J* = 7.2 Hz, 2H), 4.10 (t, *J* = 7.2 Hz, 2H), 5.99 (s, 1H), 6.99-7.01 (m, 1H), 7.03-7.07 (m, 1H), 7.18-7.20 (m, 2H), 7.25-7.26 (m, 2H), 7.28-7.33 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.9, 33.3, 49.0, 63.1, 116.3, 124.4, 127.4, 127.9, 128.1, 129.3, 132.1, 132.6, 136.5, 139.9, 144.4, 149.6, 173.6. HRMS calcd for C₂₀H₂₁N₂O: 305.1648 [M+H]⁺, found: 305.1647.



5,5,9-Trimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (**3b**)


White solid (80.4 mg, 84%), mp 155.3-156.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.66 (s, 6H), 2.20 (s, 3H), 2.77 (t, *J* = 7.6 Hz, 2H), 4.08 (t, *J* = 7.6 Hz, 2H), 5.99 (s, 1H), 6.80 (s, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.19-7.21 (m, 2H), 7.31-7.33 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 20.8, 26.8, 33.3, 49.0, 62.7,

116.2, 127.3, 128.1, 128.5, 129.2, 132.4, 132.5, 134.0, 136.7, 139.8, 144.3, 147.2, 173.2. HRMS calcd for $C_{21}H_{23}N_2O$: 319.1805 $[M+H]^+$, found: 319.1804.




9-Methoxy-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3c)

Light yellow solid (70.2 mg, 70%), mp 170.1-172.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 1.65 (s, 6H), 2.77 (t, $J = 7.2$ Hz, 2H), 3.65 (s, 3H), 4.06 (t, $J = 7.2$ Hz, 2H), 6.02 (s, 1H), 6.54 (d, $J = 2.4$ Hz, 1H), 6.81 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.4$ Hz, 1H), 7.18-7.23 (m, 3H), 7.30-7.33 (m, 3H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$) δ 26.8, 33.4, 49.1, 55.4, 62.6, 113.1, 117.2, 117.3, 127.5, 128.2, 129.2, 134.0, 136.7, 140.1, 143.1, 143.9, 156.2, 172.9. HRMS calcd for $C_{21}H_{23}N_2O_2$: 335.1754 $[M+H]^+$, found: 335.1754.




9-Fluoro-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3d)

White solid (79.3 mg, 82%), mp 168.0-169.2 °C. 1H NMR (400 MHz, $CDCl_3$) δ 1.67(s, 6H), 2.77 (t, $J = 7.2$ Hz, 2H), 4.08 (t, $J = 7.6$ Hz, 2H), 6.02 (s, 1H), 6.71 (dd, $J_1 = 9.6$ Hz, $J_2 = 2.8$ Hz, 1H), 6.95 (td, $J_1 = 8.4$ Hz, $J_2 = 2.8$ Hz, 1H), 7.18-7.23 (m, 3H), 7.32-7.35 (m, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 26.8, 33.2, 49.4, 63.1, 114.3 (d, $^2J_{C-F} = 22.4$ Hz), 117.5 (d, $^3J_{C-F} = 8.7$ Hz), 118.4 (d, $^2J_{C-F} = 23.2$ Hz), 127.6, 128.3, 129.2, 134.6 (d, $^3J_{C-F} = 7.3$ Hz), 135.6 (d, $^4J_{C-F} = 2.1$ Hz), 141.0, 143.7, 145.8 (d, $^4J_{C-F} = 2.9$ Hz), 159.4 (d, $^1J_{C-F} = 242.0$ Hz), 173.5. ^{19}F NMR (376 MHz, $CDCl_3$) δ -118.14 – -118.08 (m). HRMS calcd for $C_{20}H_{20}FN_2O$: 323.1554 $[M+H]^+$, found: 323.1553.




9-Chloro-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3e)

White solid (74.1 mg, 73%), mp 179.0-180.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.67 (s, 6H), 2.75 (t, $J = 7.2$ Hz, 2H), 4.07 (t, $J = 7.2$ Hz, 2H), 6.00 (s, 1H), 6.97 (d, $J = 2.0$ Hz, 1H), 7.17-7.23 (m, 4H), 7.32-7.36 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.8, 33.1, 49.2, 63.3, 117.5, 127.6, 127.7, 128.4, 129.2, 129.8, 131.7, 134.3, 135.3, 141.2, 143.8, 148.2, 173.6. HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{ClN}_2\text{O}$: 339.1259 $[\text{M}+\text{H}]^+$, found: 339.1242.




9-Bromo-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3f)

White solid (90.5 mg, 79%), mp 177.6-179.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.67 (s, 6H), 2.75 (t, $J = 7.2$ Hz, 2H), 4.07 (t, $J = 7.2$ Hz, 2H), 6.00 (s, 1H), 7.11-7.14 (m, 2H), 7.17-7.19 (m, 2H), 7.33-7.38 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.8, 33.1, 49.2, 63.3, 117.5, 117.9, 127.7, 128.4, 129.2, 130.5, 134.60, 134.63, 135.2, 141.3, 143.7, 148.7, 173.6. HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{BrN}_2\text{O}$: 383.0754 $[\text{M}+\text{H}]^+$, found: 383.0751.




5,5-Dimethyl-7-phenyl-9-(trifluoromethyl)-1,2-dihydro-3H,5H-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3g)

White solid (91.5 mg, 82%), mp 180.3-181.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.69 (s, 6H), 2.77 (t, $J = 7.2$ Hz, 2H), 4.13 (t, $J = 7.2$ Hz, 2H), 6.03 (s, 1H), 7.15-7.17 (m, 2H), 7.26 (s, 1H), 7.33-7.36 (m, 4H), 7.51 (d, $J = 8.4$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.9, 33.0, 49.3, 63.8, 116.4, 123.9 (q, $^1J_{\text{C-F}} = 270.1$ Hz), 124.5 (q, $^3J_{\text{C-F}} = 3.6$ Hz), 126.5 (q, $^2J_{\text{C-F}} = 32.5$ Hz), 127.8, 128.4, 129.17, 129.24 (q, $^3J_{\text{C-F}} = 3.6$ Hz), 132.9, 135.1, 141.6, 143.8, 152.5, 174.1. ^{19}F NMR (376 MHz, CDCl_3) δ -62.22 (s). HRMS calcd for $\text{C}_{21}\text{H}_{20}\text{F}_3\text{N}_2\text{O}$: 373.1522 $[\text{M}+\text{H}]^+$, found: 373.1523.




5,5-Dimethyl-3-oxo-7-phenyl-2,3-dihydro-1*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-9-carbonitrile (3h)

Light yellow solid (77.4 mg, 78%), mp 185.0-186.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.69 (s, 6H), 2.75 (t, *J* = 7.2 Hz, 2H), 4.13 (t, *J* = 7.2 Hz, 2H), 6.00 (s, 1H), 7.12-7.15 (m, 2H), 7.29 (d, *J* = 1.2 Hz, 1H), 7.31-7.36 (m, 4H), 7.54 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.9, 32.9, 49.3, 64.2, 107.9, 116.8, 118.6, 127.9, 128.6, 129.2, 131.1, 133.3, 134.2, 136.2, 142.2, 143.7, 153.4, 174.4. HRMS calcd for C₂₁H₂₀N₃O: 330.1601 [M+H]⁺, found: 330.1596.



11-Fluoro-5,5-dimethyl-7-phenyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3i)


Light yellow solid (62.8 mg, 65%), mp 183.2-184.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.62 (s, 6H), 2.85 (t, *J* = 7.2 Hz, 2H), 4.11 (t, *J* = 7.2 Hz, 2H), 6.11 (s, 1H), 6.77-6.79 (m, 1H), 7.00-7.04 (m, 2H), 7.19-7.21 (m, 2H), 7.30-7.33 (m, 3H). ¹³C{¹H} NMR(100 MHz, CDCl₃) δ 26.7, 35.0 (d, ⁵*J*_{C-F} = 7.2 Hz), 51.6 (d, ⁴*J*_{C-F} = 12.3 Hz), 62.4, 116.3 (d, ²*J*_{C-F} = 24.5 Hz), 125.5 (d, ³*J*_{C-F} = 9.3 Hz), 127.1 (d, ³*J*_{C-F} = 2.9 Hz), 127.6, 128.2, 129.0, 136.1 (d, ²*J*_{C-F} = 10.1 Hz), 137.0 (d, ⁴*J*_{C-F} = 2.9 Hz), 137.2(d, ⁴*J*_{C-F} = 2.9 Hz), 140.4, 143.9, 153.9 (d, ¹*J*_{C-F} = 243.4 Hz), 174.0. ¹⁹F NMR (376 MHz, CDCl₃) δ -119.91 (dd, *J*₁ = 10.9 Hz, *J*₂ = 5.6 Hz). HRMS calcd for C₂₀H₂₀FN₂O: 323.1554 [M+H]⁺, found: 323.1551.



5,5,10-Trimethyl-7-phenyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3j)


White solid (87.0 mg, 91%), mp 164.7-165.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.66 (s, 6H), 2.39 (s, 3H), 2.78 (t, *J* = 7.6 Hz, 2H), 4.09 (t, *J* = 7.6 Hz, 2H), 5.94 (s, 1H), 6.88 (s, 2H), 7.05 (s 1H), 7.18-7.20 (m, 2H), 7.29-7.33 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 21.7, 26.9, 33.3, 48.9, 63.0, 117.1, 125.3, 127.3, 128.1, 129.3, 129.9, 131.9, 136.5, 137.9, 139.1, 144.5, 149.4, 173.5. HRMS calcd for C₂₁H₂₃N₂O: 319.1805 [M+H]⁺, found:

319.1804.




10-Methoxy-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3k)

Brown syrup (75.1 mg, 75%). ^1H NMR (400 MHz, CDCl_3) δ 1.66 (s, 6H), 2.77 (t, $J = 7.2$ Hz, 2H), 3.82 (s, 3H), 4.06 (t, $J = 7.2$ Hz, 2H), 5.86 (s, 1H), 6.60 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.0$ Hz, 1H), 6.80 (d, $J = 2.4$ Hz, 1H), 6.92 (d, $J = 8.8$ Hz, 1H), 7.19-7.21 (m, 2H), 7.28-7.32 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.8, 33.4, 49.1, 55.4, 62.6, 113.1, 117.2, 117.3, 127.5, 128.2, 129.2, 134.0, 136.7, 140.1, 143.1, 143.9, 156.2, 172.9. HRMS calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_2$: 335.1754 $[\text{M}+\text{H}]^+$, found: 335.1754.



10-Bromo-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3l)


Light yellow solid (99.7 mg, 87%), mp 180.5-181.9 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.67 (s, 6H), 2.77 (t, $J = 7.6$ Hz, 2H), 4.07 (t, $J = 7.6$ Hz, 2H), 5.97 (s, 1H), 6.86 (d, $J = 8.4$ Hz, 1H), 7.16-7.19 (m, 3H), 7.31-7.33 (m, 3H), 7.38 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.8, 33.1, 49.2, 63.3, 117.5, 127.6, 127.7, 128.4, 129.2, 129.8, 131.7, 134.3, 135.3, 141.2, 143.8, 148.2, 173.6. HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{BrN}_2\text{O}$: 383.0754 $[\text{M}+\text{H}]^+$, found: 383.0748.



10-Fluoro-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3m)


White solid (34.8 mg, 36%), mp 153.8-154.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.67 (s, 6H), 2.77 (t, $J = 7.6$ Hz, 2H), 4.06 (t, $J = 7.6$ Hz, 2H), 5.93 (s, 1H), 6.77 (td, $J_1 = 8.0$ Hz, $J_2 = 2.4$ Hz, 1H), 6.95-6.98 (m, 2H), 7.16-7.18 (m, 2H), 7.30-7.33 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 26.9, 32.9, 49.2, 63.4, 104.1 (d, $^2J_{\text{C-F}} = 23.8$

Hz), 111.3 (d, $^2J_{C-F} = 20.9$ Hz), 127.5, 128.2, 128.6 (d, $^4J_{C-F} = 2.9$ Hz), 129.2, 133.6 (d, $^3J_{C-F} = 8.7$ Hz), 135.5, 139.5, 144.3, 151.2 (d, $^3J_{C-F} = 6.5$ Hz), 161.7 (d, $^1J_{C-F} = 247.0$ Hz), 173.6. ^{19}F NMR (376 MHz, CDCl_3) δ -112.09 – -112.02 (m). HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{FN}_2\text{O}$: 323.1554 $[\text{M}+\text{H}]^+$, found: 323.1555.




8-Fluoro-5,5-dimethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3m')

Light yellow solid (32.8 mg, 34%), mp 186.0-188.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.65 (s, 6H), 2.75 (brs, 2H), 4.07 (t, $J = 7.6$ Hz, 2H), 6.22 (s, 1H), 6.84-6.89 (m, 1H), 7.11 (d, $J = 8.0$ Hz, 1H), 7.14-7.17 (m, 2H), 7.27-7.33 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 26.8, 33.1, 49.0, 61.7, 112.4 (d, $^4J_{C-F} = 3.3$ Hz), 113.1 (d, $^2J_{C-F} = 21.9$ Hz), 120.8 (d, $^2J_{C-F} = 12.0$ Hz), 126.7, 127.3, 128.2, 129.1 (d, $^3J_{C-F} = 9.9$ Hz), 133.2, 141.8, 143.2 (d, $^4J_{C-F} = 2.3$ Hz), 151.4 (d, $^3J_{C-F} = 5.4$ Hz), 161.0 (d, $^1J_{C-F} = 250.5$ Hz), 172.1. ^{19}F NMR (376 MHz, CDCl_3) δ -101.96 (dd, $J_1 = 9.8$ Hz, $J_2 = 5.6$ Hz). HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{FN}_2\text{O}$: 323.1554 $[\text{M}+\text{H}]^+$, found: 323.1554.




2,2,5,5-Tetramethyl-7-phenyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3n)

White solid (80.7 mg, 81%), mp 166.8-167.9 °C. ^1H NMR (600 MHz, CDCl_3) δ 1.32 (s, 6H), 1.68 (s, 6H), 4.03 (s, 2H), 5.93 (s, 1H), 6.97-7.00 (m, 2H), 7.16-7.18 (m, 2H), 7.20-7.23 (m, 1H), 7.28-7.32 (m, 3H), 7.34 (d, $J = 7.8$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.7, 26.8, 42.4, 59.8, 63.8, 117.2, 123.5, 127.0, 127.2, 128.1, 129.4, 131.9, 132.4, 136.4, 139.8, 145.0, 149.7, 180.4. HRMS calcd for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}$: 333.1961 $[\text{M}+\text{H}]^+$, found: 333.1959.




5,5-Dimethyl-7-(*p*-tolyl)-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3o)

White solid (83 mg, 87%), mp 199.1-200.2 °C. ¹H NMR (600 MHz, CDCl₃) δ 1.66 (s, 6H), 2.36 (s, 3H), 2.77 (t, *J* = 7.2 Hz, 2H), 4.09 (t, *J* = 7.2 Hz, 2H), 5.98 (s, 1H), 7.01-7.06 (m, 2H), 7.08 (d, *J* = 8.4 Hz, 2H), 7.12 (d, *J* = 7.8 Hz, 2H), 7.24-7.25 (m, 2H). ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 21.2, 26.9, 33.3, 49.0, 63.0, 116.3, 124.4, 127.8, 128.8, 129.2, 132.1, 132.8, 136.4, 137.1, 139.4, 141.6, 149.5, 173.5. HRMS calcd for C₂₁H₂₃N₂O: 319.1805 [M+H]⁺, found: 319.1807.



7-(4-Methoxyphenyl)-5,5-dimethyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3p)


White solid (83.9 mg, 84%), mp 184.5-185.2 °C. ¹H NMR (600 MHz, CDCl₃) δ 1.66 (s, 6H), 2.77 (t, *J* = 7.2 Hz, 2H), 3.81 (s, 3H), 4.09 (t, *J* = 7.2 Hz, 2H), 5.98 (s, 1H), 6.83-6.85 (m, 2H), 7.03-7.07 (m, 2H), 7.10-7.13 (m, 2H), 7.25-7.26 (m, 2H). ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 26.9, 33.3, 49.0, 55.3, 62.8, 113.5, 116.3, 124.4, 127.8, 130.4, 132.1, 132.9, 136.1, 136.9, 139.0, 149.5, 159.1, 173.3. HRMS calcd for C₂₁H₂₃N₂O₂: 335.1754 [M+H]⁺, found: 335.1760.



7-(4-Fluorophenyl)-5,5-dimethyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3q)


White solid (71.5 mg, 74%), mp 193.0-194.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.67 (s, 6H), 2.77 (t, *J* = 7.2 Hz, 2H), 4.10 (t, *J* = 7.2 Hz, 2H), 5.97 (s, 1H), 6.97-7.02 (m, 3H), 7.04-7.08 (m, 1H), 7.14-7.17 (m, 2H), 7.25-7.27 (m, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.9, 33.2, 49.0, 63.0, 115.0 (d, ²*J*_{C-F} = 20.9 Hz), 116.3, 124.5, 128.0, 130.8 (d, ³*J*_{C-F} = 8.0 Hz), 132.0, 132.4, 135.5, 139.9, 140.4 (d, ⁴*J*_{C-F} = 2.8 Hz), 149.6, 162.3 (d, ¹*J*_{C-F} = 244.8 Hz), 173.5. ¹⁹F NMR (376 MHz, CDCl₃) δ -115.13 – -115.06 (m). HRMS calcd for C₂₀H₂₀FN₂O: 319.1505 [M+H]⁺, found: 319.1507.

323.1554 [M+H]⁺, found: 323.1557.




7-(4-Chlorophenyl)-5,5-dimethyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3r)

White solid (84.2 mg, 83%), mp 219.6-220.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.66 (s, 6H), 2.77 (t, *J* = 7.2 Hz, 2H), 4.10 (t, *J* = 7.6 Hz, 2H), 5.97 (s, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 7.05-7.09 (m, 1H), 7.13 (d, *J* = 8.0 Hz, 2H), 7.27-7.29 (m, 4H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.8, 33.2, 49.0, 63.1, 116.3, 124.5, 128.1, 128.3, 130.6, 131.9, 132.2, 133.3, 135.4, 140.2, 142.8, 149.6, 173.6. HRMS calcd for C₂₀H₂₀ClN₂O: 339.1259 [M+H]⁺, found: 339.1258.



7-(4-Bromophenyl)-5,5-dimethyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3s)


White solid (91.7 mg, 80%), mp 213.2-214.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.66 (s, 6H), 2.77 (t, *J* = 7.6 Hz, 2H), 4.10 (t, *J* = 7.6 Hz, 2H), 5.96 (s, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 7.04-7.08 (m, 3H), 7.26-7.30 (m, 2H), 7.44 (d, *J* = 8.0 Hz, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.8, 33.2, 49.0, 63.1, 116.3, 121.5, 124.5, 128.1, 130.9, 131.3, 131.9, 132.1, 135.4, 140.2, 143.3, 149.6, 173.6. HRMS calcd for C₂₀H₂₀BrN₂O: 383.0754 [M+H]⁺, found: 383.0760.




5,5-Dimethyl-7-(4-(trifluoromethyl)phenyl)-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-on

e (3t)

White solid (90.4 mg, 81%), mp 126.4-127.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.68 (s, 6H), 2.78 (t, *J* = 7.2 Hz, 2H), 4.12 (t, *J* = 7.2 Hz, 2H), 5.99 (s, 1H), 6.93 (d, *J* = 7.6 Hz, 1H), 7.05-7.09 (m, 1H), 7.27-7.32 (m, 4H), 7.57 (d, *J* = 8.0 Hz, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.8, 33.2, 49.1, 63.3, 116.4, 124.2 (q, ¹*J*_{C-F} = 270.8 Hz), 124.6, 125.1 (q, ³*J*_{C-F} = 3.6 Hz), 128.2, 129.5 (q, ²*J*_{C-F} = 31.8 Hz), 129.6, 131.8, 131.9, 135.3, 141.1, 148.0, 149.7, 173.8. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.40 (s). HRMS calcd for C₂₁H₂₀F₃N₂O: 373.1522 [M+H]⁺, found: 373.1527.


**5,5-Dimethyl-7-(4-nitrophenyl)-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one(3u)**

Light yellow solid (68.1 mg, 65%), mp 168.6-170.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.70 (s, 6H), 2.79 (t, *J* = 7.2 Hz, 2H), 4.12 (t, *J* = 7.6 Hz, 2H), 6.03 (s, 1H), 6.89-6.91 (m, 1H), 7.07-7.11 (m, 1H), 7.29-7.32 (m, 2H), 7.34-7.31 (m, 2H), 8.16-8.19 (m, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 26.7, 33.2, 49.1, 63.4, 116.5, 123.5, 124.7, 128.5, 130.0, 131.4, 131.8, 134.7, 141.9, 147.1, 149.8, 151.0, 173.8. HRMS calcd for C₂₀H₂₀N₃O₃: 350.1499 [M+H]⁺, found: 350.1497.

**5,5-Dimethyl-7-(o-tolyl)-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3v)**


White solid (85.9 mg, 90%), mp 132.8-134.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.69(s, 6H), 1.96 (s, 3H), 2.76 (brs, 2H), 4.11 (t, *J* = 7.2 Hz, 2H), 5.74 (s, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.94-6.98 (m, 1H), 7.13-7.16 (m, 2H), 7.17-7.24 (m, 4H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 19.7, 26.9, 33.4, 49.2, 63.8, 115.9, 124.4, 125.7, 127.38, 127.40, 130.1, 130.2, 131.1, 132.3, 135.0, 136.5, 140.4, 144.0, 148.9, 174.6. HRMS calcd for C₂₁H₂₃N₂O: 350.1717 [M+H]⁺, found: 350.1717.

319.1805 [M+H]⁺, found: 319.1808.




7-(2-Bromophenyl)-5,5-dimethyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3w)

White solid (99.7 mg, 87%), mp 177.4-179.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.71 (s, 6H), 2.77 (t, *J* = 7.2 Hz, 2H), 4.13 (t, *J* = 7.2 Hz, 2H), 5.75 (s, 1H), 6.77 (d, *J* = 7.6 Hz, 1H), 6.98-7.02 (m, 1H), 7.16-7.31 (m, 5H), 7.59 (d, *J* = 8.0 Hz, 1H). ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 26.8, 33.2, 49.0, 63.2, 116.4, 124.6, 127.46, 127.50, 128.1, 129.3, 129.4, 131.9, 132.0, 134.0, 135.3, 140.6, 146.2, 149.6, 173.7. HRMS calcd for C₂₀H₂₀BrN₂O: 383.0754 [M+H]⁺, found: 383.0757.



5,5-Dimethyl-7-(*m*-tolyl)-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3x)


White solid (78.3 mg, 82%), mp 131.1-132.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.67 (s, 6H), 2.33 (s, 3H), 2.77 (t, *J* = 7.6 Hz, 2H), 4.10 (t, *J* = 7.2 Hz, 2H), 5.98 (s, 1H), 6.98-7.02 (m, 3H), 7.04-7.08 (m, 1H), 7.11 (d, *J* = 7.6 Hz, 1H), 7.20 (t, *J* = 7.2 Hz, 1H), 7.25-7.26 (m, 2H). ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 21.4, 26.9, 33.3, 49.0, 63.0, 116.3, 124.4, 126.4, 127.8, 128.0, 128.1, 129.9, 132.2, 132.7, 136.5, 137.7, 139.7, 144.4, 149.5, 173.5. HRMS calcd for C₂₁H₂₃N₂O: 319.1805 [M+H]⁺, found: 319.1807.



7-(3-Chlorophenyl)-5,5-dimethyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3y)


Light yellow solid (74.1 mg, 73%), mp 143.0-144.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.69 (s, 6H), 2.77 (t, *J* =

7.2 Hz, 2H), 4.10 (t, $J = 7.2$ Hz, 2H), 5.97 (s, 1H), 6.98 (d, $J = 8.0$ Hz, 1H), 7.06-7.10 (m, 2H), 7.20 (s, 1H), 7.22-7.28 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 26.8, 33.2, 49.0, 63.2, 116.4, 124.6, 127.46, 127.50, 128.1, 129.3, 129.4, 131.9, 132.0, 134.0, 135.3, 140.6, 146.2, 149.6, 173.7. HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{ClN}_2\text{O}$: 339.1259 $[\text{M}+\text{H}]^+$, found: 339.1258.




5,5-Dimethyl-7-(thiophen-2-yl)-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3z)

White solid (76.3 mg, 82%), mp 174.0-176.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.64 (s, 6H), 2.76 (t, $J = 7.2$ Hz, 2H), 4.07 (t, $J = 7.2$ Hz, 2H), 6.26 (s, 1H), 6.86 (d, $J = 3.6$ Hz, 1H), 6.97 (t, $J = 4.0$ Hz, 1H), 7.14 (t, $J = 7.6$ Hz, 1H), 7.22 (d, $J = 5.2$ Hz, 1H), 7.25-7.32 (m, 2H), 7.37 (d, $J = 8.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 26.7, 33.2, 48.8, 62.3, 116.6, 124.7, 124.9, 126.7, 127.0, 128.4, 130.3, 131.7, 132.2, 139.4, 146.7, 149.2, 172.8. HRMS calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{OS}$: 311.1213 $[\text{M}+\text{H}]^+$, found: 311.1218.




7-Cyclopropyl-5,5-dimethyl-1,2-dihydro-3H,5H-benzo[c]pyrazolo[1,2-a][1,2]diazepin-3-one (3aa)

White solid (70.8 mg, 88%), mp 179.0-180.9 °C. ^1H NMR (400 MHz, CDCl_3) δ 0.61 (q, $J = 5.2$ Hz, 2H), 0.82-0.87 (m, 2H), 1.54 (s, 6H), 1.58-1.62 (m, 1H), 2.73 (t, $J = 7.2$ Hz, 2H), 4.04 (t, $J = 7.2$ Hz, 2H), 5.66 (s, 1H), 7.18-7.26 (m, 3H), 7.90 (d, $J = 7.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 7.0, 19.2, 27.0, 33.3, 49.0, 62.7, 116.1, 124.6, 127.4, 128.9, 133.5, 134.3, 135.9, 148.4, 173.6. HRMS calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}$: 269.1648 $[\text{M}+\text{H}]^+$, found: 269.1649.




5-Ethyl-5-methyl-7-phenyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3bb)

White solid (77.3 mg, 81%), mp 123.5-124.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.86 (t, *J* = 7.2 Hz, 3H), 1.60 (s, 3H), 1.63-1.72 (m, 1H), 2.53-2.62 (m, 1H), 2.68-2.75 (m, 1H), 2.83-2.91 (m, 1H), 4.03-4.10 (m, 1H), 4.14-4.21 (m, 1H), 5.92 (s, 1H), 7.01 (d, *J* = 7.6 Hz, 1H), 7.04-7.08 (m, 1H), 7.19-7.23 (m, 2H), 7.26-7.27 (m, 2H), 7.30-7.34 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 9.0, 26.3, 32.0, 33.3, 48.7, 66.7, 116.4, 124.5, 127.4, 127.8, 128.1, 129.2, 132.0, 133.0, 138.2, 144.4, 149.4, 172.8. HRMS calcd for C₂₁H₂₃N₂O: 319.1805 [M+H]⁺, found: 319.1803.



5-(*tert*-Butyl)-5-methyl-7-phenyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3cc)


White solid (69.6 mg, 67%), mp 176.2-171.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.16 (s, 9H), 1.74 (s, 3H), 2.49 (dd, *J*₁ = 16.4 Hz, *J*₂ = 6.4 Hz, 1H), 3.12-3.21 (m, 1H), 4.01 (td, *J*₁ = 13.6 Hz, *J*₂ = 6.8 Hz, 1H), 4.22 (dd, *J*₁ = 12.8 Hz, *J*₂ = 6.8 Hz, 1H), 6.19 (s, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.97-7.01 (m, 1H), 7.19-7.21 (m, 4H), 7.28-7.35 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 23.1, 27.8, 33.9, 42.7, 47.5, 72.1, 115.8, 124.0, 127.1, 127.2, 128.1, 129.5, 131.8, 132.7, 135.9, 137.1, 145.6, 150.1, 174.9. HRMS calcd for C₂₃H₂₇N₂O: 347.2118 [M+H]⁺, found: 347.2114.



5-Cyclohexyl-5-methyl-7-phenyl-1,2-dihydro-3*H*,5*H*-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3dd)


White solid (79.3 mg, 71%), mp 191.5-193.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.92-1.01 (m, 1H), 1.07-1.32 (m, 4H), 1.50-1.53 (m, 1H), 1.61-1.64 (m, 5H), 1.79-1.82 (m, 1H), 1.89-1.92 (m, 1H), 2.62-2.73 (m, 2H), 2.85-2.93 (m, 1H), 4.02-4.10 (m, 1H), 4.14-4.21 (m, 1H), 6.05 (s, 1H), 7.00 (d, *J* = 7.6 Hz, 1H), 7.04-7.08 (m, 1H), 7.19-7.22 (m, 2H), 7.25-7.27 (m, 2H), 7.31-7.34 (m, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 24.5, 26.3, 26.6,

26.8, 28.0, 28.7, 33.5, 45.4, 48.7, 69.6, 116.5, 124.6, 127.4, 127.7, 128.1, 129.2, 131.9, 133.3, 135.8, 138.0, 144.8, 149.2, 172.5. HRMS calcd for C₂₅H₂₉N₂O: 373.2274 [M+H]⁺, found: 373.2275.




7-Butyl-5,5-diethyl-1,2-dihydro-3H,5H-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (3ee)

Yellow solid (77.7 mg, 83%), mp 95.2-96.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.78 (t, *J* = 7.6 Hz, 6H), 0.88 (t, *J* = 7.2 Hz, 3H), 1.26-1.33 (m, 2H), 1.35-1.43 (m, 2H), 1.50-1.59 (m, 2H), 2.30-2.39 (m, 2H), 2.52 (t, *J* = 6.8 Hz, 2H), 2.76 (t, *J* = 7.2 Hz, 2H), 4.05 (t, *J* = 7.2 Hz, 2H), 5.58 (s, 1H), 7.14-7.21 (m, 3H), 7.42 (d, *J* = 7.6 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 8.8, 13.9, 22.3, 31.4, 31.7, 33.3, 38.5, 48.0, 69.5, 117.0, 124.9, 127.1, 128.0, 133.6, 134.2, 136.7, 148.6, 171.8. HRMS calcd for C₂₀H₂₉N₂O: 313.2274 [M+H]⁺, found: 313.2271.



7-Phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5a)


White solid (67.4 mg, 68%), mp 156.0-157.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.70-1.77 (m, 2H), 1.82-1.97 (m, 4H), 2.59-2.66 (m, 2H), 2.78 (t, *J* = 7.2 Hz, 2H), 4.07 (t, *J* = 7.2 Hz, 2H), 6.15 (s, 1H), 7.00-7.02 (m, 1H), 7.04-7.08 (m, 1H), 7.18-7.21 (m, 2H), 7.24-7.27 (m, 2H), 7.28-7.34 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 24.7, 33.5, 38.2, 48.5, 71.9, 116.8, 124.5, 127.4, 128.0, 128.2, 129.2, 131.9, 133.2, 137.1, 139.4, 144.1, 149.5, 172.3. HRMS calcd for C₂₂H₂₃N₂O: 331.1805 [M+H]⁺, found: 331.1803.



9-Methyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5b)

White solid (64.0 mg, 62%), mp 156.8-157.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.69-1.75 (m, 2H), 1.79-1.85 (m,


2H), 1.89-1.94 (m, 2H), 2.21 (s, 3H), 2.58-2.65(m, 2H), 2.78 (t, $J = 7.2$ Hz, 2H), 4.04 (t, $J = 7.2$ Hz, 2H), 6.15 (s, 1H), 6.82 (d, $J = 1.6$ Hz, 1H), 7.06-7.09 (m, 1H), 7.15 (d, $J = 8.4$ Hz, 1H), 7.19-7.21 (m, 2H), 7.29-7.34 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 20.8, 24.6, 33.6, 38.1, 48.4, 71.4, 116.8, 127.4, 128.1, 128.7, 129.1, 132.1, 133.3, 134.1, 137.5, 139.3, 144.0, 147.2, 171.9. HRMS calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}$: 345.1961 $[\text{M}+\text{H}]^+$, found: 345.1962.



9-Methyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one

(5c)

White solid (64.8 mg, 60%), mp 158.4-159.9 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.68-1.74 (m, 2H), 1.78-1.83 (m, 2H), 1.90-1.95 (m, 2H), 2.58-2.65 (m, 2H), 2.78 (t, $J = 7.2$ Hz, 2H), 3.65 (s, 3H), 4.02 (t, $J = 7.2$ Hz, 2H), 6.18 (s, 1H), 6.55 (d, $J = 3.2$ Hz, 1H), 6.81 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.8$ Hz, 2H), 7.17-7.20 (m, 2H), 7.21-7.23 (m, 2H), 7.28-7.33 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.6, 33.6, 38.0, 48.4, 72.0, 113.4, 116.7, 177.9, 127.5, 128.2, 129.1, 134.8, 137.5, 139.6, 143.1, 143.5, 156.4, 171.7. HRMS calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}_2$: 361.1911 $[\text{M}+\text{H}]^+$, found: 361.1909.




9-Chloro-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one

(5d)


Brown syrup (71.0 mg, 65%). ^1H NMR (400 MHz, CDCl_3) δ : 1.71-1.76 (m, 2H), 1.82-1.97 (m, 2H), 2.58-2.64 (m, 2H), 2.76 (t, $J = 7.2$ Hz, 2H), 4.03 (t, $J = 7.2$ Hz, 2H), 6.15 (s, 1H), 6.98 (d, $J = 2.4$ Hz, 1H), 7.16-7.24 (m, 4H), 7.30-7.36 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.8, 33.2, 38.3, 48.8, 72.2, 118.0, 127.67, 127.73, 128.4, 129.2, 129.9, 131.5, 134.8, 135.8, 140.7, 143.5, 148.2, 172.4. HRMS calcd for $\text{C}_{22}\text{H}_{22}\text{ClN}_2\text{O}$: 365.1415

$[M+H]^+$, found: 365.1411.




9-Bromo-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5e)

White solid (77.1 mg, 63%), mp 186.2-187.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.70-1.76 (m, 2H), 1.82-1.95 (m, 4H), 2.58-2.65 (m, 2H), 2.76 (t, $J = 7.2$ Hz, 2H), 4.03 (t, $J = 7.2$ Hz, 2H), 6.15(s, 1H), 7.11-7.13 (m, 2H), 7.17-7.19 (m, 2H), 7.31-7.38 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.8, 33.3, 38.3, 48.7, 72.2, 117.6, 118.3, 127.7, 128.4, 129.1, 130.7, 134.4, 135.2, 135.7, 140.8, 143.5, 148.7, 172.4. HRMS calcd for $\text{C}_{22}\text{H}_{22}\text{BrN}_2\text{O}$: 409.0910 $[M+H]^+$, found: 409.0906.



7-Phenyl-9-(trifluoromethyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5f)


White solid (72.9 mg, 61%), mp 171.0-172.7 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.71-1.80 (m, 2H), 1.88-1.99 (m, 4H), 2.59-2.66 (m, 2H), 2.77 (t, $J = 7.2$ Hz, 2H), 4.10 (t, $J = 7.2$ Hz, 2H), 6.17(s, 1H), 7.15-7.19 (m, 2H), 7.26-7.27 (m, 1H), 7.31-7.37 (m, 4H), 7.51 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.9, 33.2, 38.5, 49.0, 72.8, 116.7, 123.9 (q, $^1J_{\text{C-F}} = 270.1$ Hz), 124.6 (q, $^3J_{\text{C-F}} = 3.6$ Hz), 126.4 (q, $^2J_{\text{C-F}} = 32.5$ Hz), 127.8, 128.4, 129.1, 129.2 (q, $^3J_{\text{C-F}} = 4.4$ Hz), 133.2, 135.4, 141.0, 143.6, 152.5, 172.9. ^{19}F NMR (376 MHz, CDCl_3) δ -62.40 (s). HRMS calcd for $\text{C}_{23}\text{H}_{22}\text{F}_3\text{N}_2\text{O}$: 399.1679 $[M+H]^+$, found: 399.1671.




10-Methyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one

(5g)

White solid (74.3 mg, 72%), mp 146.3-147.8 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.70-1.75 (m, 2H), 1.80-1.96 (m, 4H), 2.39 (s, 3H), 2.58-2.65 (m, 2H), 2.78 (t, $J = 7.2$ Hz, 2H), 4.06 (t, $J = 7.2$ Hz, 2H), 6.11 (s, 1H), 6.86-6.91 (m, 2H), 7.04 (s, 1H), 7.18-7.20 (m, 2H), 7.26-7.33 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 20.8, 24.6, 33.6, 38.1, 48.4, 71.4, 116.8, 127.4, 128.1, 128.7, 129.1, 132.1, 133.3, 134.1, 137.5, 139.3, 144.0, 147.2, 171.9. HRMS calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}$: 345.1961 $[\text{M}+\text{H}]^+$, found: 345.1958.


**10-Bromo-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one****(5h)**

White solid (85.7 mg, 70%), mp 131.3-133.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.71-1.77 (m, 2H), 1.83-1.97 (m, 4H), 2.58-2.65 (m, 2H), 2.78 (t, $J = 7.2$ Hz, 2H), 4.04 (t, $J = 7.2$ Hz, 2H), 6.12 (s, 1H), 6.87 (d, $J = 8.4$ Hz, 1H), 7.15-7.19 (m, 3H), 7.29-7.34 (m, 3H), 7.36 (d, $J = 2.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 24.8, 33.2, 38.3, 48.8, 72.4, 120.0, 121.2, 127.5, 127.6, 128.3, 129.2, 132.0, 133.3, 135.9, 140.0, 143.8, 150.8, 172.5. HRMS calcd for $\text{C}_{22}\text{H}_{22}\text{BrN}_2\text{O}$: 409.0910 $[\text{M}+\text{H}]^+$, found: 409.0904.

**7-(*p*-Tolyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5i)**

White solid (77.4 mg, 75%), mp 124.2-126.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.68-1.75 (m, 2H), 1.80-1.94 (m, 4H), 2.36 (s, 3H), 2.58-2.65 (m, 2H), 2.78 (t, $J = 7.2$ Hz, 2H), 4.07 (t, $J = 7.2$ Hz, 2H), 6.13 (s, 1H), 7.02-7.13 (m, 6H), 7.23-7.27 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 21.2, 24.7, 33.5, 38.2, 48.5, 71.8, 116.8, 124.5, 128.0, 128.9, 129.0, 131.9, 133.4, 137.0, 137.1, 138.9, 141.2, 149.5, 172.2. HRMS calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}$:

345.1961 [M+H]⁺, found: 345.1957.




7-(4-Methoxyphenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one

(5j)

White solid (65.9 mg, 61%), mp 139.1-140.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.68-1.75 (m, 2H), 1.79-1.84 (m, 2H), 1.87-1.96 (m, 2H), 2.58-2.65 (m, 2H), 2.78 (t, *J* = 7.2 Hz, 2H), 3.82 (s, 3H), 4.07 (t, *J* = 7.2 Hz, 2H), 6.14 (s, 1H), 6.83-6.86 (m, 2H), 7.03-7.14 (m, 4H), 7.24-7.29 (m, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 24.6, 33.5, 38.1, 48.4, 55.3, 71.5, 113.5, 116.9, 124.6, 128.0, 130.2, 131.8, 133.6, 136.5, 136.9, 138.4, 149.5, 159.1, 172.0.

HRMS calcd for C₂₃H₂₅N₂O₂: 361.1911 [M+H]⁺, found: 361.1911.




7-(4-Chlorophenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one

(5k)


White solid (71.2 mg, 65%), mp 152.6-154.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.68-1.75 (m, 2H), 1.81-1.86 (m, 2H), 1.89-1.97 (m, 2H), 2.58-2.65 (m, 2H), 2.78 (t, *J* = 7.2 Hz, 2H), 4.07 (t, *J* = 7.2 Hz, 2H), 6.12 (s, 1H), 6.98 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 1H), 7.07 (td, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 7.11-7.14 (m, 2H), 7.24-7.29 (m, 4H).

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 24.8, 33.4, 38.2, 48.5, 72.0, 116.8, 124.6, 128.2, 128.4, 130.5, 131.8, 132.8, 133.3, 136.0, 139.7, 142.6, 149.6, 172.4. HRMS calcd for C₂₂H₂₂ClN₂O: 365.1415 [M+H]⁺, found: 365.1416.




7-(4-(Trifluoromethyl)phenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5l)

White solid (75.3 mg, 63%), mp 143.9-145.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.71-1.78 (m, 2H), 1.84-1.99 (m, 4H), 2.60-2.67 (m, 2H), 2.79 (t, *J* = 7.2 Hz, 2H), 4.08 (t, *J* = 7.2 Hz, 2H), 6.13 (s, 1H), 6.93-6.95 (m, 1H), 7.05-7.09 (m, 1H), 7.25-7.32 (m, 4H), 7.57 (d, *J* = 8.0 Hz, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 24.8, 33.4, 38.3, 48.7, 72.3, 116.8, 124.2 (q, ¹*J*_{C-F} = 270.1 Hz), 124.6, 125.2 (q, ³*J*_{C-F} = 3.7 Hz), 128.3, 129.45 (q, ²*J*_{C-F} = 31.8 Hz), 129.49, 131.8, 132.3, 135.7, 140.7, 147.8, 149.7, 172.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.22 (s). HRMS calcd for C₂₃H₂₂F₃N₂O: 399.1679 [M+H]⁺, found: 399.1674.



7-Cyclopropyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclopentan]-3-one (5m)


White solid (63.5 mg, 72%), mp 183.6-184.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.59-0.63 (m, 2H), 0.82-0.87 (m, 2H), 1.58-1.74 (m, 5H), 1.81-1.90 (m, 2H), 2.49-2.56 (m, 2H), 2.73 (t, *J* = 7.2 Hz, 2H), 4.01 (t, *J* = 7.2 Hz, 2H), 5.79 (d, *J* = 0.8 Hz, 1H), 7.16-7.18 (m, 1H), 7.20-7.28 (m, 2H), 7.88 (dd, *J*₁ = 7.6 Hz, *J*₂ = 1.6 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 7.1, 19.0, 24.7, 33.5, 38.3, 48.6, 71.7, 116.5, 124.6, 127.5, 128.8, 134.0, 134.9, 135.3, 148.4, 172.4. HRMS calcd for C₁₉H₂₃N₂O: 295.1805[M+H]⁺, found: 295.1804.



7-Phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7a)

White solid (89.8 mg, 87%), mp 162.7-164.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.31-1.40 (m, 1H), 1.56-1.74 (m,


7H), 2.63-2.70 (m, 2H), 2.80 (t, $J = 7.2$ Hz, 2H), 4.04 (t, $J = 7.2$ Hz, 2H), 6.62 (s, 1H), 7.04 (d, $J = 7.2$ Hz, 1H), 7.08-7.12 (m, 1H), 7.20-7.22 (m, 2H), 7.28-7.34 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.6, 24.8, 33.5, 34.1, 48.6, 64.8, 120.6, 121.4, 127.8, 128.0, 128.3, 129.0, 132.8, 132.9, 136.1, 137.6, 143.7, 150.7, 171.3. HRMS calcd for $\text{C}_{23}\text{H}_{25}\text{N}_2\text{O}$: 345.1961 $[\text{M}+\text{H}]^+$, found: 345.1952.



9-Methyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[c]pyrazolo[1,2-a][1,2]diazepine-5,1'-cyclohexan]-3-one

(7b)

White solid (91.3 mg, 85%), mp 181.4-183.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.30-1.36 (m, 1H), 1.55-1.73 (m, 7H), 2.23 (s, 3H), 2.62-2.68 (m, 2H), 2.79 (t, $J = 7.6$ Hz, 2H), 4.01 (t, $J = 7.6$ Hz, 2H), 6.59 (s, 1H), 6.85 (d, $J = 1.6$ Hz, 1H), 7.09 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.6$ Hz, 1H), 7.18 (d, $J = 8.4$ Hz, 1H), 7.21-7.24 (m, 2H), 7.30-7.35 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 20.8, 23.7, 24.8, 33.8, 33.9, 48.3, 64.0, 117.1, 127.6, 128.2, 129.0, 131.7, 134.0, 134.5, 135.3, 138.9, 144.0, 147.1, 170.8. HRMS calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}$: 359.2118 $[\text{M}+\text{H}]^+$, found: 359.2114.




9-Methoxy-7-phenyl-1,2-dihydro-3H-spiro[benzo[c]pyrazolo[1,2-a][1,2]diazepine-5,1'-cyclohexan]-3-one

(7c)

Light yellow solid (86.4 mg, 77%), mp 176.2-177.9 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.30-1.37 (m, 1H), 1.54-1.74 (m, 7H), 2.65 (td, $J_1 = 12.4$ Hz, $J_2 = 3.6$ Hz, 2H), 2.80 (t, $J = 7.6$ Hz, 2H), 3.67 (s, 3H), 3.99 (t, $J = 7.6$ Hz, 2H), 6.58 (d, $J = 2.8$ Hz, 1H), 6.61 (s, 1H), 6.83 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.8$ Hz, 1H), 7.20-7.28 (m, 3H), 7.29-7.34 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.7, 24.8, 33.8, 34.0, 48.4, 55.5, 63.9, 113.7, 116.2, 118.3, 127.7, 128.2, 129.0, 135.4, 135.6, 138.8, 143.0, 143.5, 156.6, 170.7. HRMS calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$:


375.2067 [M+H]⁺, found: 375.2055.



9-Fluoro-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one

(7d)


White solid (79.3 mg, 73%), mp 175.3-176.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.30-1.39 (m, 1H), 1.54-1.75 (m, 7H), 2.63-2.69 (m, 2H), 2.80 (t, *J* = 7.2 Hz, 2H), 4.01 (t, *J* = 7.2 Hz, 2H), 6.65 (s, 1H), 6.75 (dd, *J*₁ = 9.6 Hz, *J*₂ = 2.8 Hz, 1H), 6.96-7.01 (m, 1H), 7.20-7.26 (m, 3H), 7.31-7.36 (m, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.6, 24.8, 33.8, 34.0, 48.7, 64.4, 114.9 (d, ²*J*_{C-F} = 22.4 Hz), 117.7 (d, ²*J*_{C-F} = 22.4 Hz), 118.6 (d, ³*J*_{C-F} = 8.7 Hz), 127.8, 128.4, 129.0, 136.0 (d, ³*J*_{C-F} = 8.0 Hz), 136.5, 137.8 (d, ⁴*J*_{C-F} = 2.1 Hz), 143.3, 145.7 (d, ⁴*J*_{C-F} = 2.2 Hz), 159.7 (d, ¹*J*_{C-F} = 242.7 Hz), 171.1. ¹⁹F NMR (376 MHz, CDCl₃) δ -117.32 – -117.26 (m). HRMS calcd for C₂₃H₂₄FN₂O: 363.1867 [M+H]⁺, found: 363.1861.



9-Bromo-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one


(7e)

Light yellow solid (95.0 mg, 75%), mp 214.3-215.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.32-1.39 (m, 1H), 1.54-1.76 (m, 7H), 2.62-2.69 (m, 2H), 2.78 (t, *J* = 7.2 Hz, 2H), 4.00 (t, *J* = 7.2 Hz, 2H), 6.64 (s, 1H), 7.15-7.17 (m, 2H), 7.18-7.21 (m, 2H), 7.32-7.36 (m, 3H), 7.39 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.6, 24.8, 33.6, 34.0, 48.6, 64.6, 118.0, 118.9, 127.9, 128.4, 129.0, 131.0, 134.0, 136.0, 136.8, 137.4, 143.4, 148.6, 171.2. HRMS calcd for C₂₃H₂₄BrN₂O: 423.1067 [M+H]⁺, found: 423.1066.




7-Phenyl-9-(trifluoromethyl)-1,2-dihydro-3H-spiro[benzo[c]pyrazolo[1,2-a][1,2]diazepine-5,1'-cyclohexan]-3-one (7f)

White solid (103.9 mg, 84%), mp 202.3-203.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.32-1.42 (m, 1H), 1.56-1.75 (m, 7H), 2.64-2.72 (m, 2H), 2.79 (t, *J* = 7.6 Hz, 2H), 4.07 (t, *J* = 7.6 Hz, 2H), 6.70 (s, 1H), 7.16-7.20 (m, 2H), 7.30-7.38 (m, 5H), 7.54 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.6 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 23.5, 24.8, 33.5, 34.2, 48.8, 65.1, 117.4, 123.9 (q, ¹*J*_{C-F} = 270.1 Hz), 125.0 (q, ³*J*_{C-F} = 3.6 Hz), 126.9 (q, ¹*J*_{C-F} = 32.5 Hz), 128.0, 128.5, 128.7 (q, ³*J*_{C-F} = 3.6 Hz), 129.0, 134.1, 137.2, 143.6, 152.3, 171.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.22 (s). HRMS calcd for C₂₄H₂₄F₃N₂O: 413.1835 [M+H]⁺, found: 413.1829.



10-Methoxy-7-phenyl-1,2-dihydro-3H-spiro[benzo[c]pyrazolo[1,2-a][1,2]diazepine-5,1'-cyclohexan]-3-one (7g)


White solid (79.7 mg, 71%), mp 167.6-168.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.34-1.40 (m, 1H), 1.59-1.73 (m, 7H), 2.65 (td, *J*₁ = 13.2 Hz, *J*₂ = 4.0 Hz, 2H), 2.79 (t, *J* = 7.6 Hz, 2H), 3.84 (s, 3H), 4.01 (t, *J* = 7.2 Hz, 2H), 6.49 (s, 1H), 6.65 (dd, *J*₁ = 8.8 Hz, *J*₂ = 2.4 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 6.96 (d, *J* = 8.4 Hz, 1H), 7.20-7.23 (m, 2H), 7.29-7.34 (m, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 23.6, 24.8, 33.6, 33.9, 48.5, 55.5, 64.4, 104.5, 109.1, 126.7, 127.5, 128.2, 129.0, 132.6, 133.7, 138.4, 144.2, 150.7, 159.4, 171.1. HRMS calcd for C₂₄H₂₇N₂O₂: 375.2067 [M+H]⁺, found: 375.2060.




10-Bromo-7-phenyl-1,2-dihydro-3H-spiro[benzo[c]pyrazolo[1,2-a][1,2]diazepine-5,1'-cyclohexan]-3-one

(7h)

White solid (103.8 mg, 82%), mp 157.8-159.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.33-1.39 (m, 1H), 1.54-1.75 (m, 7H), 2.66 (td, $J_1 = 13.6$ Hz, $J_2 = 4.8$ Hz, 2H), 2.79 (t, $J = 7.2$ Hz, 2H), 4.01 (t, $J = 7.2$ Hz, 2H), 6.62 (s, 1H), 6.91 (d, $J = 8.4$ Hz, 1H), 7.17-7.19 (m, 2H), 7.22 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.6$ Hz, 1H), 7.31-7.34 (m, 3H), 7.40 (d, $J = 1.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.6, 24.8, 33.5, 34.1, 48.6, 64.8, 120.6, 121.4, 127.8, 128.0, 128.3, 129.0, 132.8, 132.9, 136.1, 137.6, 143.7, 150.7, 171.3. HRMS calcd for $\text{C}_{23}\text{H}_{24}\text{BrN}_2\text{O}$: 423.1067 $[\text{M}+\text{H}]^+$, found: 423.1062.


**2-Methyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7i)**

White solid (79.5 mg, 74%), mp 141.3-143.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.24 (d, $J = 6.8$ Hz, 3H), 1.32-1.82 (m, 7H), 1.97 (d, $J = 12.8$ Hz, 1H), 2.51 (td, $J_1 = 13.2$ Hz, $J_2 = 4.8$ Hz, 1H), 2.82 (td, $J_1 = 13.2$ Hz, $J_2 = 4.4$ Hz, 1H), 3.14-3.23 (m, 1H), 3.50 (t, $J = 12.8$ Hz, 1H), 4.27-4.32 (m, 1H), 6.61 (s, 1H), 7.02-7.10 (m, 2H), 7.20-7.22 (m, 2H), 7.25-7.33 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 13.8, 23.4, 23.8, 24.9, 33.2, 34.7, 37.4, 56.3, 64.5, 117.4, 124.7, 127.5, 128.1, 128.2, 129.1, 131.6, 133.9, 135.5, 138.5, 144.2, 149.5, 173.8. HRMS calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}$: 359.2118 $[\text{M}+\text{H}]^+$, found: 359.2118.

**2,2-Dimethyl-7-phenyl-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7j)****(7j)**


White solid (89.3 mg, 80%), mp 139.8-141.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.27 (s, 6H), 1.41-1.47 (m, 1H), 1.54-1.72 (m, 7H), 2.65-2.71 (m, 2H), 3.92 (s, 2H), 6.43 (s, 1H), 6.89-6.97 (m, 2H), 7.17-7.19 (m, 2H), 7.21-7.22

(m, 2H), 7.28-7.33 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.1, 24.5, 25.2, 33.8, 42.8, 62.2, 63.3, 118.5, 122.7, 127.3, 127.9, 128.2, 129.0, 131.0, 132.4, 136.6, 139.6, 144.5, 150.5, 176.1. HRMS calcd for $\text{C}_{25}\text{H}_{29}\text{N}_2\text{O}$: 373.2274 $[\text{M}+\text{H}]^+$, found: 373.2269.




7-(4-Ethylphenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7k)

White solid (99.4 mg, 89%), mp 133.6-134.9 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.25 (t, $J = 7.6$ Hz, 3H), 1.32-1.37 (m, 1H), 1.58-1.72 (m, 7H), 2.62-2.69 (m, 4H), 2.80 (t, $J = 7.2$ Hz, 2H), 4.04 (t, $J = 7.6$ Hz, 2H), 6.60 (s, 1H), 7.06-7.16 (m, 6H), 7.27-7.29 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 15.6, 23.6, 24.8, 28.6, 33.8, 33.9, 48.4, 64.3, 117.2, 124.8, 127.7, 128.2, 129.0, 131.6, 134.2, 134.9, 138.5, 141.4, 143.7, 149.4, 171.1. HRMS calcd for $\text{C}_{25}\text{H}_{29}\text{N}_2\text{O}$: 373.2274 $[\text{M}+\text{H}]^+$, found: 373.2271.




7-(4-Methoxyphenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7l)

Yellow syrup (86.6 mg, 77%). ^1H NMR (400 MHz, CDCl_3) δ 1.32-1.38 (m, 1H), 1.54-1.73 (m, 7H), 2.62-2.68 (m, 2 H), 2.80 (t, $J = 7.6$ Hz, 2H), 3.81 (s, 3H), 4.03 (t, $J = 7.6$ Hz, 2H), 6.57 (s, 1H), 6.83-6.87 (m, 2H), 7.06-7.11 (m, 2H), 7.12-7.16 (m, 2H), 7.26-7.28 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.7, 24.8, 33.8, 33.9, 48.3, 55.3, 64.2, 113.6, 117.2, 124.9, 128.3, 130.1, 131.5, 134.2, 134.3, 136.5, 138.3, 149.4, 159.3, 171.0. HRMS calcd for $\text{C}_{24}\text{H}_{27}\text{N}_2\text{O}_2$: 375.2067 $[\text{M}+\text{H}]^+$, found: 375.2059.




7-(4-(Trifluoromethyl)phenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7m)

Yellow solid (101.4 mg, 82%), mp 178.4-179.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.31-1.41 (m, 1H), 1.53-1.64 (m, 2H), 1.69-1.76 (m, 5H), 2.68 (td, *J*₁ = 13.2 Hz, *J*₂ = 4.4 Hz, 2H), 2.81 (t, *J* = 7.2 Hz, 2H), 4.05 (t, *J* = 7.2 Hz, 2H), 6.64 (s, 1H), 6.97-6.99 (m, 1H), 7.09-7.13 (m, 1H), 7.29-7.33 (m, 4H), 7.58 (d, *J* = 8.0 Hz, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 23.6, 24.8, 33.7, 33.9, 48.5, 64.6, 117.3, 124.2 (q, ¹*J*_{C-F} = 270.2 Hz), 125.0, 125.2 (q, ³*J*_{C-F} = 3.6 Hz), 128.6, 129.3, 129.6 (q, ²*J*_{C-F} = 32.5 Hz), 131.3, 133.2, 136.9, 137.4, 147.7, 149.5, 171.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.42 (s). HRMS calcd for C₂₄H₂₄F₃N₂O: 413.1835 [M+H]⁺, found: 413.1833.



7-(*m*-Tolyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7n)


Light yellow solid (92.4 mg, 86%), mp 163.0-164.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.33-1.38 (m, 1H), 1.55-1.74 (m, 7H), 2.33(s, 3H), 2.62-2.70 (m, 2H), 2.80 (t, *J* = 7.2 Hz, 2H), 4.04 (t, *J* = 7.6 Hz, 2H), 6.59 (s, 1H), 6.99-7.05 (m, 3H), 7.08-7.12 (m, 2H), 7.21 (t, *J* = 7.2 Hz, 1H), 7.26-7.29 (m, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 21.5, 23.6, 24.8, 33.8, 33.9, 48.4, 64.3, 117.2, 124.9, 126.2, 128.1, 128.2, 128.3, 129.7, 131.6, 134.1, 135.2, 137.8, 138.7, 144.1, 149.4, 171.2. HRMS calcd for C₂₄H₂₇N₂O: 359.2118 [M+H]⁺, found: 359.2114.



7-(3-Chlorophenyl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one


(7o)

White solid (99.8 mg, 88%), mp 157.8-159.3 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.33-1.40 (m, 1H), 1.53-1.63 (m, 2H), 1.68-1.75 (m, 5H), 2.63-2.69 (m, 2H), 2.80 (t, $J = 7.6$ Hz, 2H), 4.04 (t, $J = 7.6$ Hz, 2H), 6.60 (s, 1H), 7.02 (d, $J = 7.2$ Hz, 1H), 7.08-7.14 (m, 2H), 7.18 (d, $J = 1.6$ Hz, 1H), 7.23-7.32 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.6, 24.8, 33.7, 33.9, 48.5, 64.4, 117.3, 125.0, 127.3, 127.7, 128.6, 129.0, 129.5, 131.4, 133.3, 134.1, 136.3, 137.4, 145.9, 149.5, 171.3. HRMS calcd for $\text{C}_{23}\text{H}_{24}\text{ClN}_2\text{O}$: 379.1572 $[\text{M}+\text{H}]^+$, found: 379.1572.



7-(Thiophen-2-yl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7p)

White solid (85.4 mg, 81%), mp 153.8-154.5 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.26-1.38 (m, 1H), 1.50-1.72 (m, 7H), 2.63 (td, $J_1 = 12.4$ Hz, $J_2 = 4.0$ Hz, 2H), 2.80 (t, $J = 7.6$ Hz, 2H), 4.02 (t, $J = 7.6$ Hz, 2H), 6.80 (s, 1H), 6.86 (dd, $J_1 = 3.2$ Hz, $J_2 = 0.8$ Hz, 1H), 6.97 (dd, $J_1 = 5.2$ Hz, $J_2 = 3.6$ Hz, 1H), 7.16-7.20 (m, 1H), 7.23 (dd, $J_1 = 5.2$ Hz, $J_2 = 1.2$ Hz, 1H), 7.27-7.29 (m, 1H), 7.31-7.35 (m, 1H), 7.41 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.6, 24.7, 33.7, 33.8, 48.2, 64.0, 117.4, 125.0, 125.1, 126.6, 127.2, 128.8, 131.2, 132.1, 133.4, 134.8, 146.5, 149.1, 170.7. HRMS calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{OS}$: 351.1526 $[\text{M}+\text{H}]^+$, found: 351.1523.



7-(Pyridin-3-yl)-1,2-dihydro-3H-spiro[benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepine-5,1'-cyclohexan]-3-one (7q)


White solid (86.9 mg, 84%), mp 138.2-139.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.34-1.41 (m, 1H), 1.54-1.65 (m, 2H), 1.73-1.76 (m, 5H), 2.68 (td, $J_1 = 12.8$ Hz, $J_2 = 4.0$ Hz, 2H), 2.81 (t, $J = 7.6$ Hz, 2H), 4.06 (t, $J = 7.6$ Hz, 2H), 6.65 (s, 1H), 7.00-7.01 (m, 1H), 7.10-7.14 (m, 1H), 7.23-7.28 (m, 1H), 7.31-7.33 (m, 2H), 7.47 (dt, $J_1 = 8.0$ Hz, $J_2 = 2.0$ Hz, 1H), 8.55-8.57 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 23.6, 24.7, 33.7, 34.0, 48.6, 64.7, 117.3,

123.1, 125.1, 128.7, 131.1, 133.0, 135.3, 136.3, 136.9, 139.7, 148.8, 149.5, 149.8, 171.5. HRMS calcd for $C_{22}H_{24}N_3O$: 346.1914 $[M+H]^+$, found: 346.1908.

2. Structural elaborations of 3a

2.1. Synthesis of 8 from 3a

To a solution of **3a** (60.8 mg, 0.2 mmol) in MeOH/DCM (2 mL, 10/3) was added Pd/C (10 wt%, 10 mg). The mixture was stirred at room temperature under H_2 (balloon, 1 atm) for 24 h. Upon completion, it was filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **8** (58.2 mg, 95%).




5,5-Dimethyl-7-phenyl-1,2,6,7-tetrahydro-3H,5H-benzo[*c*]pyrazolo[1,2-*a*][1,2]diazepin-3-one (**8**)

White solid (58.2 mg, 95%), mp 101.1-102.4 °C. 1H NMR (400 MHz, $CDCl_3$) δ 1.53 (s, 3H), 1.65 (s, 3H), 1.78 (dd, $J_1 = 14.4$ Hz, $J_2 = 4.4$ Hz, 1H), 2.42-2.49 (m, 1H), 2.83-2.95 (m, 2H), 3.78-3.86 (m, 1H), 4.12 (ddd, $J_1 = 12.8$ Hz, $J_2 = 7.2$ Hz, $J_3 = 2.8$ Hz, 1H), 4.42 (dd, $J_1 = 12.4$ Hz, $J_2 = 4.0$ Hz, 1H), 6.83 (d, $J = 7.6$ Hz, 1H), 6.89-6.92 (m, 1H), 7.07-7.11 (m, 2H), 7.14-7.21 (m, 3H), 7.27-7.30 (m, 2H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 24.3, 27.2, 33.5, 46.9, 48.6, 48.7, 60.0, 116.4, 124.4, 126.3, 126.7, 128.3, 128.7, 132.6, 136.2, 147.7, 149.3, 173.4. HRMS calcd for $C_{20}H_{23}N_2O$: 307.1805 $[M+H]^+$, found: 307.1805.

2.2. Synthesis of 9 from 3a

To a solution of **3a** (60.8 mg, 0.2mmol) in THF (5 mL) was added $LiAlH_4$ (0.4 mL, 1M) at 0 °C. It was then stirred at room temperature for 2 h. Upon completion, it was quenched with water, concentrated and extracted with EtOAc. The combined organic layers were dried over anhydrous Na_2SO_4 , and then concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1)

as eluent to afford **9** (33.9 mg, 55%).



3-(3,3-Dimethyl-5-phenyl-2,3-dihydro-1H-benzo[*c*][1,2]diazepin-1-yl)propan-1-ol (**9**)

Yellowish syrup (33.9 mg, 55%), ^1H NMR (400 MHz, CDCl_3) δ 1.35 (s, 6H), 1.95-2.01 (m, 2H), 3.61-3.64 (m, 4H), 3.80 (t, $J = 5.6$ Hz, 2H), 6.08 (s, 1H), 6.87 (td, $J_1 = 7.2$ Hz, $J_2 = 0.8$ Hz, 1H), 6.92 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.6$ Hz, 1H), 7.04 (d, $J = 7.6$ Hz, 1H), 7.13-7.18 (m, 3H), 7.25-7.33 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 27.8, 30.2, 54.4, 61.5, 62.8, 115.4, 122.3, 126.8, 127.2, 128.0, 129.5, 130.5, 133.3, 136.2, 143.6, 146.0, 151.8. HRMS calcd for $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}$: 309.1961 $[\text{M}+\text{H}]^+$, found: 309.1962.


2.3. Gram-scale synthesis of **3a**

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 814 mg, 5 mmol), toluene (20 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (31 mg, 0.05 mmol), $\text{Zn}(\text{OAc})_2$ (460 mg, 2.5 mmol), NaOAc (205 mg, 2.5 mmol) and 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 801 mg, 5 mmol). The mixture was stirred at 100 °C (oil bath) for 10 h under air. Upon completion, it was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **3a** (1.16 g, 76%).

III. Mechanism studies


(1) H/D exchange experiments

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 32.4 mg, 0.2 mmol), toluene (2 mL), CD₃OD (0.08 mL, 2 mmol), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol), Zn(OAc)₂ (18.3 mg, 0.1 mmol) and NaOAc (8.2 mg, 0.1 mmol). The mixture was stirred at 100 °C (oil bath) for 30 min under air. The resulting mixture was cooled to room temperature, concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (1:1) as eluent to give **1a-d_n**. Upon analyzing the ¹H NMR spectrum of the product, the deuteration percentage was determined as 50%.



To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 48.7 mg, 0.3 mmol), toluene (2 mL), CD₃OD (0.12 mL, 3 mmol), [RhCp*Cl₂]₂ (4.7 mg, 0.0075 mmol), Zn(OAc)₂ (27.5 mg, 0.15 mmol), NaOAc (12.3 mg, 0.15 mmol) and 1-(phenylethynyl)cyclopentan-1-ol (**4a**, 55.8 mg, 0.3 mmol). The mixture was stirred at 100 °C (oil bath) for 30 min under air. The resulting mixture was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified



by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to give **5a-d_n**. Upon analyzing the ¹H NMR spectrum of the product, the deuteration percentage was determined as 20%.








(2) Competition experiment between **1c** and **1g**





To a reaction tube equipped with a stir bar were charged with 1-(4-methoxyphenyl)pyrazolidin-3-one (**1c**, 57.6 mg, 0.3 mmol), 1-(4-(trifluoromethyl)phenyl)pyrazolidin-3-one (**1g**, 69.0 mg, 0.3 mmol), 2-methyl-4-phenylbut-3-yn-2-ol (**2a**, 48.1 mg, 0.3 mmol), [Cp*₂RhCl₂]₂ (4.7 mg, 0.0075 mmol), Zn(OAc)₂ (27.5 mg, 0.15 mmol), NaOAc (12.3 mg, 0.15 mmol) and toluene (2 mL). The mixture was stirred at 100 °C (oil bath) for 4 h. The resulting mixture was cooled to room temperature, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **3c** (12.0 mg, 12%) and **3g** (81.4 mg, 73%).



IV. Copies of NMR spectra of 3a-3ee


































-62.223
















119.886
119.901
119.915
119.926
















7.333
7.329
7.321
7.317
7.308
7.303
7.297
7.258
7.183
7.176
7.172
7.164
7.160
6.984
6.977
6.969
6.964
6.958
6.951
6.948
6.791
6.785
6.771
6.765
6.750
6.744
5.927
4.078
4.059
4.041
2.785
2.766
2.748
1.671




173.643
162.931
160.461
151.209
151.144
144.347
139.508
135.492
133.643
133.556
129.223
128.580
128.551
128.211
127.475
111.382
111.173
104.239
104.001
77.370
77.052
76.735
63.416
49.201
32.892
26.876














101.944
101.959
101.970
101.989















7.253
7.251
7.246
7.243
7.123
7.110
7.087
7.073
7.059
7.052
7.046
7.040
7.038
7.032
7.025
7.013
5.976
4.106
4.093
4.081
2.777
2.765
2.753
2.355
1.659




173.474
149.520
141.558
139.414
137.102
136.366
132.778
132.144
129.162
128.826
127.791
124.415
116.270
77.324
77.113
76.901
62.967
49.003
33.296
26.909
21.163





















115.056
115.071
115.078
115.085
115.093
115.108
115.115
115.130








































3x







3x




































V. Copies of NMR spectra of 5a-5m









































7.293
7.289
7.275
7.268
7.259
7.255
7.239
7.135
7.128
7.124
7.107
7.098
7.093
7.078
7.072
7.064
7.054
7.049
7.033
6.863
6.856
6.835
6.828
6.135
4.085
4.066
4.048
3.818
2.801
2.783
2.764
2.647
2.627
2.612
2.597
2.581
2.577
1.955
1.937
1.921
1.917
1.902
1.882
1.873
1.843
1.827
1.815
1.799
1.794
1.786
1.751
1.739
1.730
1.715
1.702
1.692











172.039
159.103
149.482
138.432
136.929
136.525
133.592
131.823
130.248
128.009
124.557
116.850
113.527
77.370
77.052
76.735
71.534
55.312
48.371
38.107
33.499
24.644









200
150
100
50
0 PPM























V. Copies of NMR spectra of 7a-7q



















































7.279 7.271 7.269 7.263 7.158 7.150 7.145 7.134 7.129 7.121 7.111 7.101 7.091 7.080 7.077 7.058 6.866 6.859 6.854 6.842 6.837 6.830 6.570 4.047 4.028 4.009 3.809 2.814 2.795 2.776 2.680 2.658 2.648 2.626 2.617 1.727 1.722 1.690 1.652 1.606 1.575 1.549 1.352 1.332 1.323







171.006 159.284 149.381 138.273 136.510 134.257 134.242 131.491 130.147 128.255 124.889 117.247 113.578 77.479 77.161 76.843 64.174 55.312 48.320 33.925 33.810 24.825 23.669























VII. Copies of NMR spectra of 8 and 9





VIII. X-ray crystal structure and data of **3a**




Fig. S1 X-ray structure of **3a** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a petroleum ether/ethyl acetate (3:1) solution of **3a**. Crystal data collection and refinement parameters of **3a** are summarized in Table S1. Intensity data were collected at 299 K on a SuperNova Dual diffractometer using mirror-monochromated CuK α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. The structure was solved by a combination of direct methods in SHELXTL and the difference Fourier technique, and refined by full-matrix least-squares procedures. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **3a**

Empirical formula	C ₂₀ H ₂₀ N ₂ O
Formula weight	304.38
Temp, K	299.04(10)
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
<i>a</i> , Å	7.01650(10)
<i>b</i> , Å	12.2287(2)
<i>c</i> , Å	19.4244(4)
α (°)	90
β (°)	90
γ (°)	90
Volume, Å ³	1666.67(5)
<i>Z</i>	4
<i>d</i> _{calc} , g cm ⁻³	1.213
λ , Å	1.54184
μ , mm ⁻¹	0.591
No. of data collected	4511
No. of unique data	2906
<i>R</i> _{int}	0.0155
Goodness-of-fit on <i>F</i> ²	1.092
<i>R</i> ₁ , <i>wR</i> ₂ (<i>I</i> > 2σ(<i>I</i>))	0.0407, 0.1033
<i>R</i> ₁ , <i>wR</i> ₂ (all data)	0.0435, 0.1058

IX. X-ray crystal structure and data of **5a**




Fig. S2 X-ray structure of **5a** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a petroleum ether/ethyl acetate (1:3) solution of **5a**. Crystal data collection and refinement parameters of **5a** are summarized in Table S2. Intensity data were collected at 283 K on a SuperNova Dual diffractometer using mirror-monochromated MoK α radiation, $\lambda = 0.71073 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. The structure was solved by a combination of direct methods in SHELXTL and the difference Fourier technique, and refined by full-matrix least-squares procedures. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S2 Crystallographic data and structure refinement results of **5a**

Empirical formula	C ₂₂ H ₂₂ N ₂ O
Formula weight	330.41
Temp, K	283 (2)
Crystal system	monoclinic
Space group	P2 ₁ /n
<i>a</i> , Å	7.6394(5)
<i>b</i> , Å	22.9296(11)
<i>c</i> , Å	10.4410(6)
α (°)	90
β (°)	104.958(6)
γ (°)	90
Volume, Å ³	1766.96(18)
<i>Z</i>	4
<i>d</i> _{calc} , g cm ⁻³	1.242
λ , Å	0.71073
μ , mm ⁻¹	0.077
No. of data collected	13029
No. of unique data	4177
<i>R</i> _{int}	0.0397
Goodness-of-fit on <i>F</i> ²	1.045
<i>R</i> ₁ , <i>wR</i> ₂ (<i>I</i> > 2σ(<i>I</i>))	0.0581, 0.1318
<i>R</i> ₁ , <i>wR</i> ₂ (all data)	0.0815, 0.1467

X. References

- (1) C. Yang, F. Song, J. Chen and Y. Huang, *Adv. Synth. Catal.*, 2017, **359**, 3496-3502.
- (2) Z. Zhang, H. Jiang and Y. Huang, *Org. Lett.*, 2014, **16**, 5976-5979.
- (3) P. K. R. Panyam and T. Gandhi, *Adv. Synth. Catal.*, 2017, **359**, 1144-1151.
- (4) K. Feng, Y. Ban, P. Yuan, W. Lei, Q. Liu and R. Fang, *Org. Lett.*, 2019, **21**, 3131-3135.
- (5) K.-i. Fujita, Y. Takahashi, M. Owaki, K. Yamamoto and R. Yamaguchi, *Org. Lett.*, 2004, **6**, 2785-2788.